Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5R01AG057571-05 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Texas Health Resources | OTHER |
| Michigan State University | OTHER |
| National Institute on Aging (NIA) | NIH |
Not provided
Not provided
Not provided
Not provided
The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein accumulation in older adults. Amyloid beta protein is high in the brain of older adults with Alzheimer's disease. Hypertension may increase brain amyloid beta protein accumulation and affect memory and thinking ability in older adults. However, whether lowering blood pressure reduces brain amyloid beta protein and improves brain function is inconclusive.
The investigators hypothesize that treating high blood pressure alters brain pulsatility, which in turn reduces brain amyloid beta protein accumulation and improves brain structure and function.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard Care | Active Comparator | Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target. |
|
| Intensive Treatment | Experimental | Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg. |
|
| Control group subjects | No Intervention | Healthy normotensive subjects (24-hour ambulatory BP<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Standard Care | Other | Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Gray Matter Intracranial Pulsatility | Changes (12 month timepoint minus baseline) in intracranial pulsatility will be measured with CINE phase-contrast MRI. We will use the velocity-encoded CINE PC MRI to measure intracranial pulsatility. Pulsatility measured in mm per cardiac cycle | Baseline and 12-months |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Overall Average 24 Hour Systolic Blood Pressure | changes in overall average 24 hr ambulatory systolic blood pressure will be assessed SpaceLabs monitor | Baseline and 12-months |
| Changes in Overall Average 24hr Diastolic Blood Pressure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rong Zhang, PhD | University of Texas Southwestern Medical Center and Texas Health Resources | Principal Investigator |
| Wanpen Vongpatanasin, MD | University of Texas Southwestern Medical Center | Principal Investigator |
| David Zhu, PhD | Michigan State University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UT Southwestern Medical Center | Dallas | Texas | 75390 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31710528 | Derived | Gottesman RF. To INFINITY and Beyond: What Have We Learned and What Is Still Unknown About Blood Pressure Lowering and Cognition? Circulation. 2019 Nov 12;140(20):1636-1638. doi: 10.1161/CIRCULATIONAHA.119.042827. Epub 2019 Nov 11. No abstract available. |
Not provided
Not provided
Data will be shared approximately 18-24 months after the primary study publication.
Not provided
Not provided
Not provided
Not provided
85 participants enrolled include 40 (Control group subjects-no intervention) and 45 participants (undergo intervention). These 45 subjects are randomized to either Standard care or Intensive care interventions that is summarized in the table below. Control group was not randomized and they did not receive an experimental intervention but received SOC.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Standard Care | Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target. Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg. |
| FG001 | Intensive Treatment | Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg. Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg. |
| FG002 | Control Group | Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC). |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
85 participants enrolled include 40 (Control group subjects-no intervention) and 45 participants (undergo intervention). These 45 subjects are randomized to either Standard care or Intensive care interventions that is summarized in the table below. The baseline characteristics of the 40 subjects in Control group (no intervention) were not collected.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Standard Care | Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target. Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Changes in Gray Matter Intracranial Pulsatility | Changes (12 month timepoint minus baseline) in intracranial pulsatility will be measured with CINE phase-contrast MRI. We will use the velocity-encoded CINE PC MRI to measure intracranial pulsatility. Pulsatility measured in mm per cardiac cycle | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | mm/cardiac cycle | Baseline and 12-months |
|
12 months
Participants enrolled include Control group subjects (no intervention) and participants who underwent intervention. AEs monitored and collected for the subjects who were randomized to either Standard care or Intensive care interventions are summarized in the table below. The AEs for subjects in the Control group (no intervention) were not monitored and collected.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Standard Care | Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target. Standard Care: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abnormal laboratory measure | General disorders | Non-systematic Assessment | low serum sodium |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Rong Zhang | IEEM | 214-345-4245 | rongzhang@texashealth.org |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Oct 5, 2021 | Jan 22, 2025 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D003704 | Dementia |
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intensive Treatment | Other | Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg. |
|
changes in overall average 24 hr ambulatory diastolic blood pressure will be assessed SpaceLabs monitor
| Baseline and 12-months |
| Regional Cortical Thickness Via Magnetic Resonance Imaging (MRI) | Baseline and 12-months |
| Brain White Matter Hyperintensity (WMH) Via Magnetic Resonance Imaging (MRI) | White matter hyperintensities (WMH) on brain T2 fluid-attenuated inversion recovery (FLAIR) magnetic resonance images (MRI) are commonly observed in older adults over 65 years old, and more extensive in those with vascular or Alzheimer's disease type of dementia. Qualitative and quantitative WMH characterization has been used as a biomarker to assist cerebral small vessel disease diagnosis and to assess treatment effects. In this report, the size of the WMH has been assessed with the PGS software, the top performer of the deep-learning algorithms from the 2017 MICCAI WMH segmentation challenge. The unit of the WMH total size presented in this report is in mL. | Baseline and 12-months |
| Brain White Matter Microstructural Integrity Via Magnetic Resonance Imaging (MRI) | Fractional Anisotropy (FA) values are a measure of how directed diffusion is in a tissue, typically ranging from 0 to 1. A value of 0 indicates isotropic diffusion (diffusion is the same in all directions), while a value of 1 indicates highly anisotropic diffusion (diffusion is restricted to a single direction). FA is often used in diffusion tensor imaging (DTI) and is thought to reflect fiber density, axonal diameter, and myelination in white matter. | Baseline and 12-months |
| Brain Neural Network Functional Connectivity Via Magnetic Resonance Imaging (MRI) | The brain's functional connectivity, particularly within the Default Mode Network (DMN), can be assessed using functional magnetic resonance imaging (fMRI) through the correlations between the activity of the brain regions within a network. In this report, the DMN regions were identified with a seed-based approach from another clinical trial with 420 subjects of a similar population. By identifying regions of interest (ROIs) within the DMN, researchers can analyze how these regions connect and interact with each other, revealing information about brain activity and potentially aiding in the diagnosis and understanding of various neurological and psychiatric conditions. Here, the functional connectivity of the DMN brain regions is reported in the unit of Pearson correlation R, with a range of 0 to 1 in this application. A high R value indicates a high level of connectivity. | Baseline and 12-months |
| NIH PROMIS Patient-reported Outcome Measures of Physical Health | PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Four items are used to assess global physical health. Three of these are administered using five-category response scales, and one item (rating of pain on average) uses a response scale of 0-10 that is recoded to five categories (0 = 1; 1-3 = 2; 4-6 = 3; 7-9 = 4; 10 = 5). T-score Metric: PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function).A score of 60 is one standard deviation above the average population | Baseline and 12-months |
| NIH PROMIS Patient-reported Outcome Measures of Mental Health | PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Four items are used to assess global physical health. Three of these are administered using five-category response scales, and one item (rating of pain on average) uses a response scale of 0-10 that is recoded to five categories (0 = 1; 1-3 = 2; 4-6 = 3; 7-9 = 4; 10 = 5). T-score Metric: PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). A score of 60 is one standard deviation above the average population | Baseline and 12-months |
| BG001 | Intensive Treatment | Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg. Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg. |
| BG002 | Control Group | Control group subjects-no intervention- not randomized. This includes Healthy normotensive subjects (24-hour ambulatory BP<125/75 mmHg without use of antihypertensive medication) who undergo MRI as part of standard of care (SOC). |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Intensive Treatment | Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg. Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg. |
|
|
| Secondary | Changes in Overall Average 24 Hour Systolic Blood Pressure | changes in overall average 24 hr ambulatory systolic blood pressure will be assessed SpaceLabs monitor | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | mmHg | Baseline and 12-months |
|
|
|
| Secondary | Changes in Overall Average 24hr Diastolic Blood Pressure | changes in overall average 24 hr ambulatory diastolic blood pressure will be assessed SpaceLabs monitor | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | mmHg | Baseline and 12-months |
|
|
|
| Secondary | Regional Cortical Thickness Via Magnetic Resonance Imaging (MRI) | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | mm | Baseline and 12-months |
|
|
|
| Secondary | Brain White Matter Hyperintensity (WMH) Via Magnetic Resonance Imaging (MRI) | White matter hyperintensities (WMH) on brain T2 fluid-attenuated inversion recovery (FLAIR) magnetic resonance images (MRI) are commonly observed in older adults over 65 years old, and more extensive in those with vascular or Alzheimer's disease type of dementia. Qualitative and quantitative WMH characterization has been used as a biomarker to assist cerebral small vessel disease diagnosis and to assess treatment effects. In this report, the size of the WMH has been assessed with the PGS software, the top performer of the deep-learning algorithms from the 2017 MICCAI WMH segmentation challenge. The unit of the WMH total size presented in this report is in mL. | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | ml | Baseline and 12-months |
|
|
|
| Secondary | Brain White Matter Microstructural Integrity Via Magnetic Resonance Imaging (MRI) | Fractional Anisotropy (FA) values are a measure of how directed diffusion is in a tissue, typically ranging from 0 to 1. A value of 0 indicates isotropic diffusion (diffusion is the same in all directions), while a value of 1 indicates highly anisotropic diffusion (diffusion is restricted to a single direction). FA is often used in diffusion tensor imaging (DTI) and is thought to reflect fiber density, axonal diameter, and myelination in white matter. | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | Mean fractional anisotropy from DTI | Baseline and 12-months |
|
|
|
| Secondary | Brain Neural Network Functional Connectivity Via Magnetic Resonance Imaging (MRI) | The brain's functional connectivity, particularly within the Default Mode Network (DMN), can be assessed using functional magnetic resonance imaging (fMRI) through the correlations between the activity of the brain regions within a network. In this report, the DMN regions were identified with a seed-based approach from another clinical trial with 420 subjects of a similar population. By identifying regions of interest (ROIs) within the DMN, researchers can analyze how these regions connect and interact with each other, revealing information about brain activity and potentially aiding in the diagnosis and understanding of various neurological and psychiatric conditions. Here, the functional connectivity of the DMN brain regions is reported in the unit of Pearson correlation R, with a range of 0 to 1 in this application. A high R value indicates a high level of connectivity. | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | Pearson correlation R (r value) | Baseline and 12-months |
|
|
|
| Secondary | NIH PROMIS Patient-reported Outcome Measures of Physical Health | PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Four items are used to assess global physical health. Three of these are administered using five-category response scales, and one item (rating of pain on average) uses a response scale of 0-10 that is recoded to five categories (0 = 1; 1-3 = 2; 4-6 = 3; 7-9 = 4; 10 = 5). T-score Metric: PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function).A score of 60 is one standard deviation above the average population | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | T score | Baseline and 12-months |
|
|
|
| Secondary | NIH PROMIS Patient-reported Outcome Measures of Mental Health | PROMIS® (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. Four items are used to assess global physical health. Three of these are administered using five-category response scales, and one item (rating of pain on average) uses a response scale of 0-10 that is recoded to five categories (0 = 1; 1-3 = 2; 4-6 = 3; 7-9 = 4; 10 = 5). T-score Metric: PROMIS measures use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population. A score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). A score of 60 is one standard deviation above the average population | Data was not collected for the Control group subjects since the investigator never planned to assess this outcome measure using Control group subject data as part of the pre-specified outcomes in the protocol. | Posted | Mean | Standard Deviation | T sore | Baseline and 12-months |
|
|
|
| 0 |
| 19 |
| 0 |
| 19 |
| 8 |
| 19 |
| EG001 | Intensive Treatment | Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg. Intensive Treatment: Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg. | 0 | 26 | 0 | 26 | 7 | 26 |
|
| Orthostatic hypotension | General disorders | Non-systematic Assessment |
|
| Dizziness | General disorders | Non-systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
Not provided
Not provided
| D009422 | Nervous System Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |